| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Executive VP and CLO | Executive VP and CLO
1 company
Boulding Mark Elliott serves as an Executive VP and CLO at PTCT. Across recent SEC filings that breaks down to 0 buys and 166 sells. Those positions are worth an estimated $6.8M at current prices.
Historically, Boulding Mark Elliott's trades have earned a middling insider score of 56/100 across 50 rated trades. Over a 12-month horizon, 33.3% of those trades were profitable, with an average 12-month return of -12.1%.
The biggest single holding is PTCT (~$6.8M) as Executive VP and CLO. The recent filings there lean toward selling, a net 671,251 shares.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Mar 11, 2025 | PTCT Ptc Therapeutics, Inc. | Executive VP and CLO | Sale+OE10b5-1 | 75,420 | $53.08 | $4,003,304.97 | -42.1% | -1.7% | +24.9% | |
| Feb 20, 2025 | PTCT Ptc Therapeutics, Inc. | Executive VP and CLO | Sell10b5-1 | 2,947 | $50.11 | $147,678.10 | -2.8% | -8.3% | +40.3% | |
| Jan 8, 2025 | PTCT Ptc Therapeutics, Inc. | Executive VP and CLO | Sell10b5-1 | 3,541 | $44.87 | $158,870.62 | -3.2% | -11.7% | +70.6% | |
| Dec 3, 2024 | PTCT Ptc Therapeutics, Inc. | Executive VP and CLO | Sale+OE10b5-1 | 95,908 | $52.37 | $5,022,334.27 | -50.9% | +5.1% | +50.6% | |
| Jan 30, 2024 | PTCT Ptc Therapeutics, Inc. | Executive VP and CLO | Sell10b5-1 | 794 | $27.25 | $21,637.14 | -1.1% | +21.0% | +70.3% | |
| Jan 9, 2024 | PTCT Ptc Therapeutics, Inc. | Executive VP and CLO | Sell10b5-1 | 3,395 | $28.85 | $97,959.60 | -4.5% | -6.4% | +56.9% | |
| Apr 17, 2023 | PTCT Ptc Therapeutics, Inc. | Executive VP and CLO | Sale+OE10b5-1 | 61,923 | $51.42 | $3,183,830.19 | -45.1% | -25.1% | -51.0% | |
| Jan 31, 2023 | PTCT Ptc Therapeutics, Inc. | Executive VP and CLO | Sell | 812 | $45.63 | $37,049.94 | -1.1% | +20.2% | -43.1% | |
| Jan 11, 2023 | PTCT Ptc Therapeutics, Inc. | Executive VP and CLO | Sell | 1,085 | $43.58 | $47,288.41 | -1.4% | +6.1% | -37.1% | |
| Jan 9, 2023 | PTCT Ptc Therapeutics, Inc. | Executive VP and CLO | Sell | 835 | $41.66 | $34,782.93 | -1.1% | +16.9% | -31.0% |